Receptor-type tyrosine-protein phosphatase mu (PTPRM)

Receptor-type tyrosine-protein phosphatase mu (PTPRM) is a transmembrane enzyme of the protein tyrosine phosphatase (PTP) family, encoded by the PTPRM gene. It features extracellular domains for cell-cell adhesion (MAM domain, immunoglobulin-like domain, fibronectin type III repeats) and intracellular phosphatase domains mediating dephosphorylation of tyrosine residues on proteins. PTPRM regulates diverse biological processes, including signal transduction, cell adhesion (particularly cadherin-mediated), neural development (guidance and outgrowth), and vascular permeability. Alterations in PTPRM have been linked to cancer progression (notably glioblastoma and lung cancer) and neurodevelopmental disorders. No drugs targeting PTPRM are approved, but its expression/methylation serve as molecular cancer biomarkers. Safety considerations for potential therapies include risks to normal cell adhesion and neural/vascular function.

Other names

PTPRMPTPRL1Protein-tyrosine phosphatase muR-PTP-muRPTPUhR-PTPuR-PTP-MURPTPMreceptor-type tyrosine-protein phosphatase muprotein tyrosine phosphatase muprotein tyrosine phosphatase, receptor type, mu polypeptide

Not applicable as there are no approved drugs; theoretically, inhibitors or modulators would alter tyrosine dephosphorylation and thus impact cell adhesion and signal transduction.